MDMB-5Br-INACA
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| Chemical and physical data | |
| Formula | C15H18BrN3O3 |
| Molar mass | 368.231 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
MDMB-5Br-INACA is an indazole-3-carboxamide derivative which has been sold as a designer drug.[1] Surprisingly it appears to produce cannabinoid activity despite the lack of a "tail" group at the indazole 1-position, but is of relatively low potency and has been encountered being misrepresented as other illicit drugs such as MDMA.[2]
See also
References
- ↑ "CFSRE Analysis Report" (PDF). Indianapolis-Marion County Forensic Services Agency. 17 May 2022.
- ↑ "Drug testers warn of new synthetic cannabinoid being sold as MDMA". New Zealand Herald. 5 August 2022.
| Phytocannabinoids (comparison) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Allosteric CBR ligands |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Receptor (ligands) |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transporter (modulators) |
| ||||||||||||
| Enzyme (modulators) |
| ||||||||||||
| Others |
| ||||||||||||
| |||||||||||||
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.